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We report a case that documents the second known patient treated by anti-TNFa who has been
diagnosed a cerebral toxoplasmosis.
ã 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
The patient was a 64-year-old Caucasian woman, treated by
adalimumab for an erosive rheumatoid arthritis (RA).
While the clinical response was satisfactory, she has presented
a ﬁrst epileptic seizure, without other neurological sign, 2 months
after the beginning of adalimumab.
Brain CT and brain MRI revealed multiple bilateral supra-
tentorial ring-shaped brain lesions, enhanced after injection of a
contrast agent.
Diagnostic stereotactic brain biopsy revealed lymphocytic and
plasma cells inﬁltration, and Toxoplasma gondii DNA by PCR on the
brain biopsy was positive, conﬁrming the diagnosis of cerebral
toxoplasmosis.
Our case report illustrates the increased risk of toxoplasmosis in
RA patients treated with anti-TNFa therapy. Indeed, it is suspected
that the IFN-g adalimumab-related inhibitory effect may favor
T. gondii replication and reactivation.
Introduction
We report a case that documents the second known patient
treated by anti-TNFa who has been diagnosed as cerebral
toxoplasmosis.
Case presentation
The patient was a 64-year-old Caucasian woman, and has been
followed in rheumatology for one year for an erosive rheumatoid
arthritis (RA), rheumatoid factor positive, anti–citrullinated
protein antibody (ACPA) negative. She was ﬁrst treated by
methotrexate, and an anti-TNF-a, etanercept 50mg every week,
was prescribed 5 months later due to insufﬁcient response.
Eventually, a loss of efﬁcacy appeared about 3 months after
biotherapy’s onset, and adalimumab 40mg every 2 weeks was
startedwith the concomitant pursuit ofmethotrexate 20mgonce a
week, and prednisone 10mg per day. While the clinical response
was satisfactory, she presented with a ﬁrst tonic-clonic seizure,
without other neurological sign, 2 months after the beginning of
adalimumab. Brain CT and brain MRI revealed multiple bilateral
supratentorial ring-shaped brain lesions, enhanced after injection
of a contrast agent (Fig. 1). PET-scan showed hypometabolism next
to parenchymal brain lesions (Fig. 2). Paraclinical exams were
performed, such as PET scan, colonoscopy, gastroscopy, mammog-
raphy, and ENT examination, assuming that there were neoplastic
lesions, but no primary cancer was found.
Lumbar puncture did not reveal any abnormality (1 element/
mm3 (lymphocyte), no red blood cell, cerebrospinal ﬂuid protein
38mg/dl, no hypoglycorrhachia, Toxoplasmosis PCR negative and
no cancer cells). HIV serologywas negative. Diagnostic stereotactic
brain biopsy revealed lymphocytic and plasma cells inﬁltration,
mainly perivascular, with wide areas of acetowhite necrosis,
containing very small round structures. Special stains of PAS,
Grocott and Ziehl were negative. Immunostaining anti-CD20 was
positive for medium perivascular cells and immunostaining anti-
CD3 was positive for a lot of small reactive lymphocytes.
Immunostaining anti-toxoplasmosis was positive for many small
round structures in the acetowhite necrosis areas. Toxoplasma
gondiiDNA by PCR on the brain biopsywas positive, conﬁrming the
diagnosis of cerebral toxoplasmosis.
Toxoplasmosis serology (latex test agglutination) was positive
(IgM 0.59U/ml, IgG 1653U/ml, IgA 10U/ml; Architect, Abbott), and
conﬁrmed that the patient has presented a toxoplasmosis
seroreactivation, documented by a strong rise of immunoglobulins
G and A, comparatively to a serology done one year before (IgM
0.19U/ml and IgG 5U/ml). Serology done one year prior to
presentation shows evidence of immunity to Toxoplasma gondii
with low IgG and negative IgM, likely related to previous* Corresponding author.
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asymptomatic infection. Date of the seroconversion could not been
detailed, due to a lack of blood serum within 6 months.
Treatments by adalimumab and methotrexate were inter-
rupted, and a treatment by sulfamethoxazole 1600milligrams
(mg) and trimethoprim 320mg twice a day was initiated, with a
concomitant folinic acid supplementation. The dose had to be
decreased due to acute renal failure, and a treatment by
sulfamethoxazole 800mg and trimethoprim 160mg twice a day
has been continuing.
Discussion
This is the second observation of a cerebral toxoplasmosis in a
RA patient treated by anti-TNF-a [1]. The diagnosis was undoubted
because Toxoplasma gondii DNA by PCR on the brain biopsy was
positive, even though PCR on the CSF was negative, which has
already been described [2,3]. With the report of two patients
treated by anti-TNF-a who developed toxoplasmic chorioretinitis
[4], our case report illustrates the increased risk of toxoplasmosis
in RA patients treated with anti-TNF-a therapy. It should be noted
that a similar case has also been described in a patient with a
spondylo-arthritis [5]. Indeed, it is suspected that the IFN-g
adalimumab-related inhibitory effect may favor T. gondii replica-
tion and reactivation [6].
As the patient was treated by anti-TNF-a, it is apparently an
endogenous reactivation of the parasite, from toxoplasma tissue
cyst, either directly in brain, or in other organs with parasitaemia
and secondary brain involvement.
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Fig. 1. Brain CT.
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Fig. 2. Brain PET-scan.
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